• Molecular NameEmedastine
  • SynonymEmedastina [INN-Spanish]; Emedastine difumarate; Emedastinum [INN-Latin]
  • Weight302.422
  • Drugbank_IDDB01084
  • ACS_NO87233-61-2
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)3.04
  • pkaN/A
  • LogD (pH=7, predicted)0.26
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-1.84
  • LogSw (predicted, AB/LogsW2.0)0.23
  • Sw (mg/ml) (predicted, ACD/Labs)0.06
  • No.of HBond Donors0
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds5
  • TPSA33.53
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn antihistamine used in eye drops to treat allergic conjunctivitis.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability50.0
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmTwo primary metabolites, 5-hydroxyemedastine and 6-hydroxyemedastine, are excreted in the urine as both free and conjugated forms. The 5'-oxoanalogs of 5-hydroxyemedastine and 6-hydroxy-emedastine and the N-oxide are also formed as minor metabolites.
  • Half life3~4 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySomnolence and malaise have been reported following daily oral administration.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A